 The FDA has accepted for review Fennec Pharmaceuticals Incs NASDAQ: FENC resubmitted marketing application seeking approval for Pedmark formulated sodium thiosulfate to prevent ototoxicity induced by cisplatin chemotherapy. The application covers patients one month to 18 years of age with localized, non-metastatic, solid tumors. 